These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28890071)

  • 1. Serum lipid alterations in GBA-associated Parkinson's disease.
    Guedes LC; Chan RB; Gomes MA; Conceição VA; Machado RB; Soares T; Xu Y; Gaspar P; Carriço JA; Alcalay RN; Ferreira JJ; Outeiro TF; Miltenberger-Miltenyi G
    Parkinsonism Relat Disord; 2017 Nov; 44():58-65. PubMed ID: 28890071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
    Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
    Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
    Barkhuizen M; Anderson DG; Grobler AF
    Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.
    Neumann J; Bras J; Deas E; O'Sullivan SS; Parkkinen L; Lachmann RH; Li A; Holton J; Guerreiro R; Paudel R; Segarane B; Singleton A; Lees A; Hardy J; Houlden H; Revesz T; Wood NW
    Brain; 2009 Jul; 132(Pt 7):1783-94. PubMed ID: 19286695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.
    Winder-Rhodes SE; Evans JR; Ban M; Mason SL; Williams-Gray CH; Foltynie T; Duran R; Mencacci NE; Sawcer SJ; Barker RA
    Brain; 2013 Feb; 136(Pt 2):392-9. PubMed ID: 23413260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
    Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
    J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodromal substantia nigra sonography undermines suggested association between substrate accumulation and the risk for GBA-related Parkinson's disease.
    Arkadir D; Dinur T; Becker Cohen M; Revel-Vilk S; Tiomkin M; Brüggemann N; Cozma C; Rolfs A; Zimran A
    Eur J Neurol; 2019 Jul; 26(7):1013-1018. PubMed ID: 30714262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation.
    Galvagnion C; Marlet FR; Cerri S; Schapira AHV; Blandini F; Di Monte DA
    Brain; 2022 Apr; 145(3):1038-1051. PubMed ID: 35362022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease.
    Galper J; Balwani M; Fahn S; Waters C; Krohn L; Gan-Or Z; Dzamko N; Alcalay RN
    Mov Disord; 2021 Jun; 36(6):1451-1455. PubMed ID: 33570220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
    Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia.
    Blauwendraat C; Reed X; Krohn L; Heilbron K; Bandres-Ciga S; Tan M; Gibbs JR; Hernandez DG; Kumaran R; Langston R; Bonet-Ponce L; Alcalay RN; Hassin-Baer S; Greenbaum L; Iwaki H; Leonard HL; Grenn FP; Ruskey JA; Sabir M; Ahmed S; Makarious MB; Pihlstrøm L; Toft M; van Hilten JJ; Marinus J; Schulte C; Brockmann K; Sharma M; Siitonen A; Majamaa K; Eerola-Rautio J; Tienari PJ; ; Pantelyat A; Hillis AE; Dawson TM; Rosenthal LS; Albert MS; Resnick SM; Ferrucci L; Morris CM; Pletnikova O; Troncoso J; Grosset D; Lesage S; Corvol JC; Brice A; Noyce AJ; Masliah E; Wood N; Hardy J; Shulman LM; Jankovic J; Shulman JM; Heutink P; Gasser T; Cannon P; Scholz SW; Morris H; Cookson MR; Nalls MA; Gan-Or Z; Singleton AB
    Brain; 2020 Jan; 143(1):234-248. PubMed ID: 31755958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada.
    Han F; Grimes DA; Li F; Wang T; Yu Z; Song N; Wu S; Racacho L; Bulman DE
    Int J Neurosci; 2016; 126(5):415-21. PubMed ID: 26000814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.
    Taguchi YV; Liu J; Ruan J; Pacheco J; Zhang X; Abbasi J; Keutzer J; Mistry PK; Chandra SS
    J Neurosci; 2017 Oct; 37(40):9617-9631. PubMed ID: 28847804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort.
    Crosiers D; Verstraeten A; Wauters E; Engelborghs S; Peeters K; Mattheijssens M; De Deyn PP; Theuns J; Van Broeckhoven C; Cras P
    Neurosci Lett; 2016 Aug; 629():160-164. PubMed ID: 27397011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual short-term memory deficits associated with GBA mutation and Parkinson's disease.
    Zokaei N; McNeill A; Proukakis C; Beavan M; Jarman P; Korlipara P; Hughes D; Mehta A; Hu MT; Schapira AH; Husain M
    Brain; 2014 Aug; 137(Pt 8):2303-11. PubMed ID: 24919969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study.
    Mielke MM; Maetzler W; Haughey NJ; Bandaru VV; Savica R; Deuschle C; Gasser T; Hauser AK; Gräber-Sultan S; Schleicher E; Berg D; Liepelt-Scarfone I
    PLoS One; 2013; 8(9):e73094. PubMed ID: 24058461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
    da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
    J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
    Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
    Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.